Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites.
about
Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladderDirect binding studies on ileal and cardiac muscarinic receptorsHuman muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonistsThe pharmacological treatment of urinary incontinence.Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.Subclassification of atrial and intestinal muscarinic receptors of the rat--direct binding studies with agonists and antagonistsManagement of overactive bladder syndromeBehavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction.Overactive bladder: diagnosis and treatment.Oxybutynin: past, present, and future.A review of flavoxate hydrochloride in the treatment of urge incontinence.Urinary incontinence in men: current and developing therapy options.Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: comparison with hippocampal M1, atrial M2 and ileal M3 receptors.Role of muscarinic receptor subtypes in central antinociception.Dicyclomine discriminates between M1- and M2-muscarinic receptors in the guinea-pig ileum.Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle.
P2860
Q26824182-7B63E961-9A14-4C67-9FF6-8B9BC556AF7CQ28361575-7E67762E-D590-4264-AACB-162198A13DABQ28367879-186E2920-5F8E-4B89-AD12-891795269439Q33778812-F5DDED6B-717F-4906-BB3B-3C72B481CB29Q34285907-7235A555-9EB9-44A1-979D-DF5602A72891Q35756475-E1C33DEC-71D1-4E7D-BF5A-9DD129198817Q36875672-1939E5AA-46B6-4F1D-A07A-2CC6A2D0E092Q37484824-F55A8219-ACA2-4EDF-9E9F-6CD161F957FFQ37699370-A4F7E6DB-EF0D-4FD1-B9C9-17F8512DA05BQ38043396-41A9DF39-0FFA-49EA-AD1C-97589631FB83Q38195179-A053A61A-477E-45C3-88A2-D7B35B136224Q38708104-192B7F45-D7AA-49D4-A14E-A29D3503B8DAQ41783065-50EBF2F5-BF79-4D14-970F-BEA062A86FFEQ41847231-01DFD2BB-0D54-4E7D-8574-405F423BB4EAQ41917425-E412485A-8FB1-4F74-AFE0-403A88C4AFA6Q42651945-EAB6C2C5-E839-4190-8E27-489167376DA8Q46464922-05DA75A7-D102-4F4F-9393-C8300777813F
P2860
Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh-hant
name
Dicyclomine, benzhexol and oxy ...... s of muscarinic binding sites.
@en
Dicyclomine, benzhexol and oxy ...... s of muscarinic binding sites.
@nl
type
label
Dicyclomine, benzhexol and oxy ...... s of muscarinic binding sites.
@en
Dicyclomine, benzhexol and oxy ...... s of muscarinic binding sites.
@nl
prefLabel
Dicyclomine, benzhexol and oxy ...... s of muscarinic binding sites.
@en
Dicyclomine, benzhexol and oxy ...... s of muscarinic binding sites.
@nl
P1476
Dicyclomine, benzhexol and oxy ...... s of muscarinic binding sites.
@en
P2093
P304
P356
10.1016/0014-2999(86)90697-7
P407
P577
1986-04-01T00:00:00Z